etapidi can help people with GC/GEJC respond to treatment and live longer
etapidi + chemotherapy was studied in a clinical trial of nearly 1,000 people who had GC or GEJC. Those included in the trial:
- Had cancer that had spread
- Could not have their cancer removed with surgery
- Had not received treatment for this stage of their cancer
With etapidi + chemotherapy, people typically lived longer:
More people who received etapidi + chemotherapy (21% of patients) were still alive at 3 years than those who received placebo + chemotherapy (14% of patients).
At 3 years with TEVIMBRA + chemotherapy
More people were still alive than those who received placebo + chemotherapy (21% vs 13% of patients)
*Placebo is an inactive treatment used to compare with active treatments.
GC, gastric cancer; GEJC, gastroesophageal junction cancer.